Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025.
Markus Magerl, M.D., Professor of Dermatology and Allergy at the Charité Universitätsmedizin Berlin Institute of Allergology, will present the design of the global Phase 3 trial of navenibart in a presentation of poster number 617 titled, 'ALPHA-ORBIT – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Adolescent and Adult Participants with Type 1 and Type 2 Hereditary Angioedema (HAE).'
Joshua S. Jacobs, M.D., Medical Director of Allergy and Asthma Clinical Research, Inc., will present attack severity reduction data from the ALPHA-STAR Phase 1b/2 trial of navenibart in a presentation of poster number 606 titled, 'Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial.'
Chunxia Lily Zhao, Ph.D., Director of Antibody Discovery at Astria Therapeutics, will present information on the profile of STAR-0310 in poster number 697 titled, 'Preclinical Data Supporting the Differentiated Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody.'
All three presentations will take place in a poster session titled 'Atopic Dermatitis, Contact Dermatitis, Urticaria, Angioedema' beginning at 9:45am PST on March 2, 2025, in the Convention Center, Ground Level, Hall A.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
SOURCE: Astria Therapeutics, Inc.
Copyright Business Wire 2025.
PUB: 02/20/2025 08:00 AM/DISC: 02/20/2025 08:00 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
OFA Group Announces Exercise and Closing of Underwriter's Full Over-Allotment Option in Connection with Initial Public Offering
Los Angeles, California--(Newsfile Corp. - June 5, 2025) - OFA Group (NASDAQ: OFAL) (the "Company"), an integrated architecture and technology firm, today announced that the underwriter of its previously announced initial public offering (the "Offering") of 3,750,000 ordinary shares have exercised its option in full to purchase an additional 562,500 ordinary shares at the public offering price of $4.00 per share. The issuance and sale of these additional shares closed today. After giving effect to the full exercise of the over-allotment option, the total number of ordinary shares sold by the Company in the Offering increased to 4,312,500 ordinary shares and the gross proceeds increased to $17,250,000 before deducting underwriting discounts and commissions. R.F. Lafferty & Co., Inc. ("R.F. Lafferty") served as sole underwriter for the Offering. A registration statement on Form F-1 (File No. 333-285103) relating to the Offering, as amended, was filed with the Securities and Exchange Commission (the "SEC") on April 11, 2025 and was declared effective by the SEC on May 15, 2025. The Offering was made only by means of a prospectus. Copies of the final prospectus related to the Offering can be obtained from: R.F. Lafferty by email at offerings@ or via standard mail to R.F. Lafferty & Co., Inc, 40 Wall Street, 27th Floor, New York, NY10005. In addition, copies of the prospectus relating to the Offering can be obtained via the SEC's website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation, or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About OFA Group OFA Group, through its wholly owned operating subsidiary, Office for Fine Architecture Limited, provides comprehensive architectural services, including design and fit out services for commercial and residential buildings. The Company's mission is to leverage its expertise in architectural design to maximize the potential of every property, ensuring that its unique attributes are highlighted and enhanced. At the forefront of architectural innovation, the Company is developing proprietary AI technologies that aims to enhance the Company's architectural design services by integrating cutting-edge artificial intelligence with human expertise. The Company is committed to innovation, efficiency, and scalability at the intersection of architectural excellence and technological advancement. Forward-Looking Statements This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements although not all forward-looking statements contain these identifying words. These forward-looking statements include statements relating to the expected trading commencement and closing dates, expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of the prospectus filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Investor & Media Contacts:CORE IR(212) 655-0924 Justin Kulik, VP Investor RelationsJustin@ Kati Waldenburg, Managing Director, Public RelationsKati@ To view the source version of this press release, please visit
Yahoo
25 minutes ago
- Yahoo
PLUG Q1 Earnings Call: Revenue Beat Estimates, Europe and Cost Cuts in Focus
Fuel cell technology Plug Power (NASDAQ:PLUG) exceeded the market's revenue expectations in Q1 CY2025, but sales rose 11.2% year on year to $133.7 million. Is now the time to buy PLUG? Find out in our full research report (it's free). Revenue: $133.7 million (11.2% year-on-year growth) Revenue Guidance for Q2 CY2025 is $160 million at the midpoint, above analyst estimates of $158.1 million Market Capitalization: $982.2 million Plug Power's first quarter results reflected renewed momentum in its material handling business and operational progress in hydrogen production. Management pointed to a major initial order from a key customer, as well as expanded partnerships in Europe, as drivers of business activity. CEO Andy Marsh noted the Louisiana hydrogen plant was commissioned on schedule, joining existing facilities in Georgia and Tennessee to boost internal production capacity. Plug Power launched its 'Quantum Leap' cost-saving program, which management claims has already realized a significant portion of targeted savings across manufacturing, logistics, sourcing, and overhead. Marsh emphasized, 'Our Q1 cash burn was down nearly 50% year-over-year and with Quantum Leap, we expect further reductions in cash burns in future quarters.' The company also raised equity and secured structured financing to reinforce liquidity amid industry headwinds. Looking ahead, Plug Power's outlook centers on expanding its presence in Europe's rapidly developing electrolyzer market, while managing uncertainties in U.S. policy. Management highlighted an active project pipeline in Europe, where new regulatory mandates and funding programs are supporting large-scale green hydrogen adoption. Jose Luis Crespo, General Manager of European operations, explained, 'Europe is a fully active electrolyzer market and Plug is in the pole position on project visibility, regulatory fit and delivery readiness.' However, Marsh cautioned about evolving U.S. energy policy, particularly surrounding hydrogen tax credits and tariffs, which may affect domestic project economics. The company is closely monitoring legislative developments and expects European projects to contribute meaningfully to bookings and revenue over the next 18 to 24 months. Plug Power's management attributed quarterly performance to progress in manufacturing efficiency, cost control initiatives, and European market expansion, while also noting policy uncertainties impacting U.S. operations. Cost Reduction Initiatives: The Quantum Leap program was launched to achieve over $200 million in annualized run-rate cost savings, focusing on manufacturing, sourcing, logistics, and SG&A. Management said most targeted savings have already been executed, leading to a nearly 50% year-over-year reduction in cash burn and further improvements expected. European Electrolyzer Momentum: Plug Power expanded its European presence, positioning itself for large-scale projects supported by regulatory mandates, funding incentives, and enforceable compliance deadlines. The company is actively participating in hydrogen projects across Denmark, Spain, Portugal, and the UK, emphasizing its 'full stack offering' and local engineering teams. Hydrogen Production Ramp-Up: The company commissioned its Louisiana hydrogen plant on time, increasing internal production capacity alongside facilities in Georgia and Tennessee. Plug Power highlighted improved operational efficiency at these sites, with the Georgia plant achieving record production and Louisiana benefiting from lessons learned in earlier builds. Customer and Market Diversification: Management reported both expansion with existing material handling customers and penetration into new accounts, including new projects with logistics firms and cold chain operators in Europe. These activities are seen as supporting future revenue stability. Tariff and Policy Mitigation: Recent U.S. tariffs on Chinese imports impacted some core product lines, prompting a multi-pronged strategy: adding potential surcharges, dual sourcing, product redesign, and further geographic diversification. Management emphasized that the electrolyzer platform is minimally affected due to its non-Chinese content. Plug Power's guidance is driven by European market expansion, continued cost reductions, and navigation of U.S. policy changes affecting hydrogen incentives and tariffs. European Project Pipeline: Management sees Europe as the most active opportunity for electrolyzer sales, with enforceable mandates and funding programs supporting sustained growth. The company expects multi-gigawatt contribution to bookings and revenue in the next 18 to 24 months as projects move from backlog to commissioning. Continued Cost Discipline: Plug Power aims to reach gross margin breakeven by year-end, supported by further reductions in cash burn through the Quantum Leap savings program. Management believes discipline in manufacturing and sourcing will help mitigate external cost pressures and improve profitability. U.S. Policy and Tariff Uncertainty: Ongoing debate around U.S. clean energy tax credits (such as Section 45V) and increased tariffs on Chinese components introduce uncertainty for domestic project economics. Plug Power is closely monitoring legislative developments and has implemented mitigation strategies, but acknowledges potential impacts on future U.S. projects. In the coming quarters, the StockStory team will watch (1) how Plug Power executes on its European electrolyzer project pipeline and converts backlog into revenue; (2) the company's ability to achieve further cost reductions and make progress toward gross margin breakeven; and (3) the impact of evolving U.S. policy and tariffs on hydrogen project economics. Developments around the Texas hydrogen facility and broader adoption of hydrogen in material handling will also be important signposts. Plug Power currently trades at a forward price-to-sales ratio of 1.1×. Should you double down or take your chips? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
Yahoo
30 minutes ago
- Yahoo
How major US stock indexes fared Thursday, 6/5/2025
U.S. stocks drifted lower as financial markets locked in their final moves before a highly anticipated update coming Friday about the U.S. job market. The S&P 500 fell 0.5% Thursday. The Dow Jones Industrial Average lost 0.3%, and the Nasdaq composite sank 0.8%. Tesla tumbled as the relationship between CEO Elon Musk soured with President Donald Trump, while Procter & Gamble fell after saying it would cut up to 7,000 jobs over the next two years. Treasury yields held relatively steady after Trump said trade talks are set to resume with China following an encouraging phone call with the leader of the world's second-largest economy. On Thursday: The S&P 500 fell 31.51 points, or 0.5%, to 5,939.30. The Dow Jones Industrial Average fell 108 points, or 0.3%, to 42,319.74. The Nasdaq composite fell 162.04 points, or 0.8%, to 19,298.45. The Russell 2000 index of smaller companies fell 1.13 points, or 0.1%, to 2,097.35. For the week: The S&P 500 is up 27.61 points, or 0.5%. The Dow is up 49.67 points, or 0.1%. The Nasdaq is up 184.68 points, or 1%. The Russell 2000 is up 31.07 points, or 1.5%. For the year: The S&P 500 is up 57.67 points, or 1%. The Dow is down 224.48 points, or 0.5%. The Nasdaq is down 12.34 points, or 0.1%. The Russell 2000 is down 132.80 points, or 6%.
